



January 11, 2019

## In This Issue

Advertising Flu Shots as "Free" is Misleading

Drug Schedule Amendment -  
Esomeprazole

Epinephrine Ampoules Back to  
Schedule I

Plan B®

Last Call for Nominations

---

## Continuing Education

### Smoking Cessation

Recorded version

[More info](#)

Guidelines available at medSask

[More info](#)

### Western Canadian One Health Antimicrobial Stewardship Conference: Inspiring and Aligning Action

January 22-24 - In-person

[Poster](#)

[Agenda](#)

### CAPhO Conference for Pharmacy Technicians

February 9, 2019 - Streamed Live

[More info](#)

### Cannabinoids / Medical Cannabis

February 12, 2019 - Telehealth

[More info](#)

## Advertising Flu Shots as "Free" is Misleading

Even though the annual flu shot may not be an out-of-pocket expense for Saskatchewan residents, it doesn't mean the services are free.

### What's wrong with using the term "free?"

It violates SCPP Regulatory Bylaws. Section 17(2)(b) of Part J states:

*"No pharmacist, pharmacy technician, or any firm, corporation, partnership, organization, or clinic operating a pharmacy, shall publish, display, distribute, or use or cause or permit, directly or indirectly, the publication, display, distribution or use of any advertisement, announcement or information related to professional services, which includes information that is false, misleading, fraudulent, deceptive, ambiguous or confusing or likely to mislead or deceive the public because, in context, it makes only partial disclosure of relevant facts;*

If a third party is paying for the service, it is not free, and patients should be aware that there is a cost to their provincial health plan and the province.

### Offering Inducements on Flu Vaccines

In addition, as per Drug Plan and Extended Benefits Branch (DPEBB), patients cannot be provided with inducements of any kind on the flu vaccine. This includes being entered into a draw, offers of free food and/or treats, or any other type of bonus offer that would be in combination with, or resulting from, receiving a flu shot at that pharmacy.

---

## Drug Schedule Amendment - Esomeprazole

The following Interim Recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) became effective November 13, 2018.

**Drug Schedule I:** Prescription Drugs includes those drugs listed in the National Drug Schedule I maintained by the National Association of Pharmacy Regulatory Authorities (NAPRA) except those drugs as may be added or amended by Council from time to time. Drugs in Schedule I may only be sold by a licensed pharmacist or licensed pharmacy technician to the public for human or animal use pursuant to a prescription unless specified otherwise for animal use in Prescription Drug List of the Food and Drug Regulations (Canada).

**Drug Schedule III:** Self-Selection area of the Pharmacy includes those drugs listed in the National Drug Schedule III maintained by the National Association of Pharmacy Regulatory Authorities (NAPRA) except those drugs as may be added or amended by Council from time to time. Drugs in Schedule III can only be sold from a pharmacy. The drug may be sold to the public without a prescription and be located in the self-selection area of the pharmacy when a pharmacist is available, accessible and approachable to assist the public with selecting the drug.

CAPhO Conference  
"Personal Medicine"

April 25-28, 2019 - Halifax

[More info](#)

Oncology Conference

May 11, 2019

[More info](#)

---

For up-to-the-minute information, news and events, visit the homepage of the SCPP website: [www.saskpharm.ca](http://www.saskpharm.ca).

MicroSCOPE is published by the Saskatchewan College of Pharmacy Professionals (SCPP) and includes decisions on matters such as regulations, drug schedule changes, etc. MicroSCOPE is emailed to all active members of the College and SCPP expects all members are aware of these matters.

To download a PDF of this e-newsletter, click [here](#).

This is to confirm:

Schedule I: esomeprazole or its salts, EXCEPT when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole.

Schedule III: esomeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole.

This means that products containing **esomeprazole or its salts** has been retained in Schedule I, which **may only be sold by a pharmacist to the public for human use pursuant to a prescription** EXCEPT when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes no greater than 280 mg. These products have been granted Schedule III status and **may only be sold from a pharmacy**. The drug may be sold to the public without a prescription and be **located in the self-selection area** of the pharmacy when a pharmacist is available, accessible and approachable to assist the public with selecting the drug.

---

## Epinephrine Ampoules Back to Schedule I

At the December meeting, Council decided not to extend the [temporary bylaw](#) that came into effect on August 27, 2018, which moved epinephrine ampoules from Schedule I to Schedule II for the treatment of anaphylaxis due to allergens.

Therefore, effective December 31, 2018, epinephrine ampoules for anaphylaxis are no longer Schedule II and are back on Schedule I status.

---

## Plan B®

The SCPP office has been receiving questions from members and the public regarding Plan B® (levonorgestrel)

*The Pharmacy and Pharmacy Disciplines Act, SS 1996, c P-9.1* allows for "scheduling by reference," which means SCPP now follows the National Association of Pharmacy Regulatory Authorities (NAPRA) scheduling requirements without having to submit a bylaw for approval for each product schedule change. However, there are some exceptions to the NAPRA schedules, which can be found at the end of the Administrative Bylaws (Schedule I and Schedule II) and at the end of the Regulatory Bylaws (Schedule III).

Presently, Plan B® (levonorgestrel) is a Schedule II drug in Saskatchewan and as such, the [Supplemental Standards of Practice for Schedule II and III Drugs](#) are to be followed when selling the product to a member of the public.

## Drug Schedule II – Pharmacy Only Restricted Access Non-Prescription Drugs

Drug Schedule II includes those drugs listed in the [National Drug Schedule II](#) maintained by NAPRA except those drugs as follows and as may be added or amended by Council from time to time.

Schedule II drugs may be sold by a licensed pharmacist or licensed pharmacy technician to the public without a prescription. These drugs must, at all times, be kept or stored in a secure location in the pharmacy, such as the dispensary, that is not accessible to the public. The licensed pharmacist must be involved in the sale of these drugs, which includes arriving at the decision to sell the drug.

Drugs INCLUDED in SCPP Schedule II:

- Levonorgestrel when sold in concentrations of 1.5 mg or less per oral dosage unit when packaged and labelled for emergency contraception

Questions regarding billing may be directed to the [Pharmacy Association of Saskatchewan \(PAS\)](#) or the [Drug Plan and Extended Benefits Branch](#).

---

# Last Call for Award Nominations

## Deadline for all SCPP award nominations is January 31, 2019

The SCPP Awards and Honours Committee is making a last call for nominations for their annual awards. These awards will be presented to members who have made a significant contribution to the pharmacy profession and/or community. Please consider those who have made a contribution and submit a nomination.

Members are welcome to nominate either their colleague(s) or themselves for any of the awards. Nominations must be accompanied by a summary of the qualifications consistent with the terms of reference.

For a complete list of awards, criteria, nomination forms, click [here](#). For a list of past award recipients, click [here](#).

**The deadline for receipt of nominations is January 31, 2019. In all cases, the selections must be approved by SCPP Council, following recommendation from the Awards and Honours Committee.**

## Special Notice for Retired SCPP Members

Have you previously been a practising or non-practising member of SCPP in good standing for at least 25 years? If so, you may be eligible to apply for the designation 'Member Emeritus Saskatchewan College of Pharmacy Professionals' or 'MESCPP'.

For more information, please click [here](#)